Partnership to support women with medically induced menopause

Jean Hailes for Women’s Health and Inherited Cancers Australia have teamed up to ensure Australian women facing medically induced menopause are not overlooked in the national conversation about this critical health issue.

With World Menopause Day on 18 October, the two organisations are highlighting the urgent need for better support and resources for women experiencing medically induced menopause due to cancer treatments or risk-reducing surgeries.

A recent national survey conducted by Inherited Cancers Australia revealed more than three-quarters (76%) of respondents who had undergone tube or ovary removal for cancer treatment or risk reduction had not accessed a menopause specialist, with many unaware that such support was even available.

Sarah Powell, CEO of Inherited Cancers Australia, said the findings underscore a critical need in our healthcare system.

“Women undergoing cancer treatment or preventative surgeries face the additional challenge of sudden menopause, often without adequate support or information.”

In response to this identified need, Jean Hailes and Inherited Cancers Australia are launching the Medically Induced Menopause Support Project. This collaborative initiative aims to develop tailored resources and support systems for women experiencing treatment-induced menopause.

CEO of Jean Hailes Dr Sarah White said, “The unique needs of these women require specialised care and support. By offering a range of evidence-based options and support, we can ensure that no woman feels isolated in her journey through medically induced menopause.”

Medically induced menopause can be caused by: chemotherapy; radiation therapy to the pelvic area; surgical removal of the ovaries (oophorectomy); or medical menopause where hormone production is shut down with medicine, such as Lupron or Zoladex.

Common symptoms include hot flushes, night sweats, vaginal dryness and mood changes. Women may also face increased long-term health risks, such as osteoporosis and cardiovascular disease.

The project will include focus groups and a national survey to gather insights directly from affected women, with the data intended to inform the development of comprehensive resources and support strategies.

“While menopausal hormone therapy (MHT) can be beneficial for many women, it’s not suitable for everyone, particularly some cancer survivors,” White said.

“Our partnership aims to explore and provide support for all women facing medically induced menopause, regardless of their ability to use hormone therapy.”

Image credit: iStock.com/nathan4847